Literature DB >> 22496215

Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus.

Markus J Hofer1, Wen Li, Peter Manders, Rachael Terry, Sue Ling Lim, Nicholas J C King, Iain L Campbell.   

Abstract

Interferon (IFN) signaling is crucial for antiviral immunity. While type I IFN signaling is mediated by STAT1, STAT2, and IRF9, type II IFN signaling requires only STAT1. Here, we studied the roles of these signaling factors in the host response to systemic infection with lymphocytic choriomeningitis virus (LCMV). In wild-type (WT) mice and mice lacking either STAT2 or IRF9, LCMV infection was nonlethal, and the virus either was cleared (WT) or established persistence (STAT2 knockout [KO] and IRF9 KO). However, in the case of STAT1 KO mice, LCMV infection was lethal and accompanied by severe multiorgan immune pathology, elevated expression of various cytokine genes in tissues, and cytokines in the serum. This lethal phenotype was unaltered by the coabsence of the gamma interferon (IFN-γ) receptor and hence was not dependent on IFN-γ. Equally, the disease was not due to a combined defect in type I and type II IFN signaling, as IRF9 KO mice lacking the IFN-γ receptor survived infection with LCMV. Clearance of LCMV is mediated normally by CD8(+) T cells. However, the depletion of these cells in LCMV-infected STAT1 KO mice was delayed, but did not prevent, lethality. In contrast, depletion of CD4(+) T cells prevented lethality in LCMV-infected STAT1 KO mice and was associated with a reduction in tissue immune pathology. These studies highlight a fundamental difference in the role of STAT1 versus STAT2 and IRF9. While all three factors are required to limit viral replication and spread, only STAT1 has the unique function of preventing the emergence of a lethal antiviral CD4(+) T-cell response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496215      PMCID: PMC3393544          DOI: 10.1128/JVI.07147-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  112 in total

1.  Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus.

Authors:  Shenghua Zhou; Anna M Cerny; An Zacharia; Katherine A Fitzgerald; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice.

Authors:  Philipp A Lang; Mike Recher; Nadine Honke; Stefanie Scheu; Stephanie Borkens; Nicole Gailus; Caroline Krings; Andreas Meryk; Andreas Kulawik; Luisa Cervantes-Barragan; Nico Van Rooijen; Ulrich Kalinke; Burkhard Ludewig; Hans Hengartner; Nicola Harris; Dieter Häussinger; Pamela S Ohashi; Rolf M Zinkernagel; Karl S Lang
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms.

Authors:  Alejandro V Villarino; Eugenio Gallo; Abul K Abbas
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

4.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

5.  Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Authors:  Dennis A Bente; Judie B Alimonti; Wun-Ju Shieh; Gaëlle Camus; Ute Ströher; Sherif Zaki; Steven M Jones
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

6.  A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells.

Authors:  Angel N Morrow; Hana Schmeisser; Takaya Tsuno; Kathryn C Zoon
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

7.  Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection.

Authors:  Gregory A Zornetzer; Matthew B Frieman; Elizabeth Rosenzweig; Marcus J Korth; Carly Page; Ralph S Baric; Michael G Katze
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

8.  The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9.

Authors:  Markus J Hofer; Wen Li; Sue Ling Lim; Iain L Campbell
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

9.  Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection.

Authors:  Ethan A Mack; Lara E Kallal; Delia A Demers; Christine A Biron
Journal:  MBio       Date:  2011-08-09       Impact factor: 7.867

Review 10.  Type I interferon modulates the battle of host immune system against viruses.

Authors:  Young-Jin Seo; Bumsuk Hahm
Journal:  Adv Appl Microbiol       Date:  2010       Impact factor: 5.086

View more
  27 in total

1.  Orf Infection in a Patient with Stat1 Gain-of-Function.

Authors:  Sara Sebnem Kilic; Anne Puel; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2014-11-04       Impact factor: 8.317

2.  Distinct PLZF+CD8αα+ Unconventional T Cells Enriched in Liver Use a Cytotoxic Mechanism to Limit Autoimmunity.

Authors:  Huiming Sheng; Idania Marrero; Igor Maricic; Shaohsuan S Fanchiang; Sai Zhang; Derek B Sant'Angelo; Vipin Kumar
Journal:  J Immunol       Date:  2019-09-25       Impact factor: 5.422

3.  IRF7-dependent type I interferon production induces lethal immune-mediated disease in STAT1 knockout mice infected with lymphocytic choriomeningitis virus.

Authors:  Wen Li; Markus J Hofer; So Ri Jung; Sue-Ling Lim; Iain L Campbell
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

4.  Cryptococcus strains with different pathogenic potentials have diverse protein secretomes.

Authors:  Leona T Campbell; Anna R Simonin; Cuilan Chen; Jannatul Ferdous; Matthew P Padula; Elizabeth Harry; Markus Hofer; Iain L Campbell; Dee A Carter
Journal:  Eukaryot Cell       Date:  2015-04-03

5.  Nonstructural Protein 11 of Porcine Reproductive and Respiratory Syndrome Virus Induces STAT2 Degradation To Inhibit Interferon Signaling.

Authors:  Liping Yang; Jia He; Rong Wang; Xinheng Zhang; Shaoli Lin; Zexu Ma; Yanjin Zhang
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

6.  Type II interferon promotes differentiation of myeloid-biased hematopoietic stem cells.

Authors:  Katie A Matatall; Ching-Chieh Shen; Grant A Challen; Katherine Y King
Journal:  Stem Cells       Date:  2014-11       Impact factor: 6.277

7.  The differential interferon responses of two strains of Stat1-deficient mice do not alter susceptibility to HSV-1 and VSV in vivo.

Authors:  Sarah Katzenell; Yufei Chen; Zachary M Parker; David A Leib
Journal:  Virology       Date:  2014-01-14       Impact factor: 3.616

8.  Type I interferon-regulated gene expression and signaling in murine mixed glial cells lacking signal transducers and activators of transcription 1 or 2 or interferon regulatory factor 9.

Authors:  Wen Li; Markus J Hofer; Pattama Songkhunawej; So Ri Jung; Dale Hancock; Gareth Denyer; Iain L Campbell
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

9.  IRF9 Prevents CD8+ T Cell Exhaustion in an Extrinsic Manner during Acute Lymphocytic Choriomeningitis Virus Infection.

Authors:  Magdalena Huber; Tamara Suprunenko; Thomas Ashhurst; Felix Marbach; Hartmann Raifer; Svenja Wolff; Thomas Strecker; Barney Viengkhou; So Ri Jung; Hannah-Lena Obermann; Stefan Bauer; Haifeng C Xu; Philipp A Lang; Adomati Tom; Karl S Lang; Nicholas J C King; Iain L Campbell; Markus J Hofer
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

10.  CD8 T Cells and STAT1 Signaling Are Essential Codeterminants in Protection from Polyomavirus Encephalopathy.

Authors:  Taryn E Mockus; Colleen S Netherby-Winslow; Hannah M Atkins; Matthew D Lauver; Ge Jin; Heather M Ren; Aron E Lukacher
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.